128 related articles for article (PubMed ID: 30539832)
1. Comparisons of skin toxicity in patients with extranodal nasal-type natural killer/T-cell lymphoma after treatment with intensity-modulated radiotherapy and conventional radiotherapy.
Gu Y; Yu H; Zuo X; Cao Q; Liang T; Ren Y; Yang H; Yang D
J Cancer Res Ther; 2018 Dec; 14(Supplement):S975-S979. PubMed ID: 30539832
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results.
Shen Q; Ma X; Hu W; Chen L; Huang J; Guo Y
Radiat Oncol; 2013 Jun; 8():152. PubMed ID: 23800149
[TBL] [Abstract][Full Text] [Related]
3. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.
Wang H; Li YX; Wang WH; Jin J; Dai JR; Wang SL; Liu YP; Song YW; Wang ZY; Liu QF; Fang H; Qi SN; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1115-21. PubMed ID: 21514070
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric comparison of helical tomotherapy, VMAT, fixed-field IMRT and 3D-conformal radiotherapy for stage I-II nasal natural killer T-cell lymphoma.
Liu X; Huang E; Wang Y; He Y; Luo H; Zhong M; Qiu D; Li C; Yang H; He G; Zhou J; Jin F
Radiat Oncol; 2017 Apr; 12(1):76. PubMed ID: 28449713
[TBL] [Abstract][Full Text] [Related]
5. A comparison of volumetric modulated arc therapy and sliding-window intensity-modulated radiotherapy in the treatment of Stage I-II nasal natural killer/T-cell lymphoma.
Liu X; Yang Y; Jin F; He Y; Zhong M; Luo H; Qiu D; Li C; Yang H; He G; Wang Y
Med Dosim; 2016; 41(1):42-6. PubMed ID: 26428072
[TBL] [Abstract][Full Text] [Related]
6. A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural killer/T-cell lymphoma.
Tomita N; Kodaira T; Tachibana H; Nakamura T; Nakahara R; Inokuchi H; Mizoguchi N; Takada A
Br J Radiol; 2009 Aug; 82(981):756-63. PubMed ID: 19366734
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of the Bolus in Intensity-Modulated Radiotherapy and Volumetric-Modulated Arc Therapy for Stage I-II Nasal Natural Killer/T-Cell Lymphoma.
Liu X; Wang Y; Guo Q; Luo H; Luo Q; Li Q; Wu Z; Jin F
Oncol Res Treat; 2020; 43(4):140-145. PubMed ID: 32018254
[TBL] [Abstract][Full Text] [Related]
8. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome.
Bi XW; Li YX; Fang H; Jin J; Wang WH; Wang SL; Liu YP; Song YW; Ren H; Dai JR
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1086-93. PubMed ID: 24120822
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 Clinical Trial of Simultaneous Boost Intensity Modulated Radiation Therapy With 3 Dose Gradients in Patients With Stage I-II Nasal Type Natural Killer/T-Cell Lymphoma: Long-Term Outcomes of Survival and Quality of Life.
Niu S; Li Y; Shao H; Hu J; Wang J; Wang H; Zhang Y
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):770-780. PubMed ID: 37939733
[TBL] [Abstract][Full Text] [Related]
10. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
[No Abstract] [Full Text] [Related]
11. Volumetric intensity-modulated arc therapy vs conventional intensity-modulated radiation therapy in nasopharyngeal carcinoma: a dosimetric study.
White P; Chan KC; Cheng KW; Chan KY; Chau MC
J Radiat Res; 2013 May; 54(3):532-45. PubMed ID: 23188186
[TBL] [Abstract][Full Text] [Related]
12. A dosimetric comparison of volumetric modulated arc therapy (VMAT) and non-coplanar intensity modulated radiotherapy (IMRT) for nasal cavity and paranasal sinus cancer.
Jeong Y; Lee SW; Kwak J; Cho I; Yoon SM; Kim JH; Park JH; Choi EK; Song SY; Kim YS; Kim SS; Joo JH; Ahn SD
Radiat Oncol; 2014 Aug; 9():193. PubMed ID: 25175383
[TBL] [Abstract][Full Text] [Related]
13. Application of 3D-print silica bolus for nasal NK/T-cell lymphoma radiation therapy.
Dai G; Xu X; Wu X; Lei X; Wei X; Li Z; Xiao Q; Zhong R; Bai S
J Radiat Res; 2020 Nov; 61(6):920-928. PubMed ID: 32960262
[TBL] [Abstract][Full Text] [Related]
14. Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group.
Wu T; Yang Y; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Hu C; Qi SN; Chen B; Li YX
Blood Adv; 2018 Sep; 2(18):2369-2377. PubMed ID: 30242098
[TBL] [Abstract][Full Text] [Related]
15. Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I
Wang HY; Niu SQ; Yang YY; Li YY; Chen HB; Zhang YJ
Cancer Med; 2018 Dec; 7(12):5863-5869. PubMed ID: 30484966
[TBL] [Abstract][Full Text] [Related]
16. Left breast irradiation with tangential intensity modulated radiotherapy (t-IMRT) versus tangential volumetric modulated arc therapy (t-VMAT): trade-offs between secondary cancer induction risk and optimal target coverage.
Karpf D; Sakka M; Metzger M; Grabenbauer GG
Radiat Oncol; 2019 Sep; 14(1):156. PubMed ID: 31477165
[TBL] [Abstract][Full Text] [Related]
17. Skin Toxicity in Early Breast Cancer Patients Treated with Field-In-Field Breast Intensity-Modulated Radiotherapy versus Helical Inverse Breast Intensity-Modulated Radiotherapy: Results of a Phase III Randomised Controlled Trial.
Joseph K; Vos LJ; Gabos Z; Pervez N; Chafe S; Tankel K; Warkentin H; Ghosh S; Amanie J; Powell K; Polkosnik LA; Horsman S; MacKenzie M; Sabri S; Parliament MB; Mackey J; Abdulkarim B
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):30-39. PubMed ID: 32711920
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of clinical efficacy of intensity-modulated radiation therapy and the prognosis factors in advanced cervical cancer].
Gao K; Ding L; Li L
Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):30-5. PubMed ID: 24694915
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.
Qi F; Wang WH; He XH; Chen B; Gui L; Fang H; Liu P; Wang SL; Yang JL; Song YW; Yang S; Qi SN; Zhou SY; Li YX; Dong M
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):61-70. PubMed ID: 30102205
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric Evaluation of Different Intensity-Modulated Radiotherapy Techniques for Breast Cancer After Conservative Surgery.
Zhang F; Wang Y; Xu W; Jiang H; Liu Q; Gao J; Yao B; Hou J; He H
Technol Cancer Res Treat; 2015 Oct; 14(5):515-23. PubMed ID: 25311257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
